Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03016325 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 329
- Enrollment target
NCT03016325 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 329 participants.
The verdict
NCT03016325, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 329 participants
- Enrollment target
Study Summary
A Study to Evaluate Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of HNO Donor in Hospitalized Patients with Heart Failure and Impaired Systolic Function
Interventions
- DRUG Placebo
- DRUG HNO Donor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2017-01-13 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03016325
The ClinicalTrials.gov registry entry for NCT03016325 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03016325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03016325 about?
NCT03016325 is a clinical study titled "Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure". A Study to Evaluate Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of HNO Donor in Hospitalized Patients with Heart Failure and Impaired Systolic Function
What is the current status of trial NCT03016325?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 329 participants. The study started on 2017-01-13. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT03016325?
The interventions under investigation include: Placebo (DRUG), HNO Donor (DRUG).
Who is sponsoring clinical trial NCT03016325?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.